Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gordon

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Pharmacoeconomics - Open|September 15, 2022
Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling StudyTetsuya Matsumoto, Akira Yuasa, Ryan Miller, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 24, 2007
Cost-utility analysis when not everyone wants the treatment: modeling split-choice biasRichard Lilford, Alan Girling, David Braunholtz, et al.
Cardiovascular Diabetology|January 21, 2009
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational studyPeter Sharplin, Jason Gordon, John R Peters, et al.
Cardiovascular Diabetology|February 18, 2009
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysisPeter Sharplin, Jason Gordon, John R Peters, et al.
Pharmacoeconomics - Open|July 3, 2021
Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision MakingJason Gordon, Angela Stainthorpe, Beverley Jones, et al.
European Journal of Gastroenterology & Hepatology|November 7, 2015
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UKPhil McEwan, Hayley Bennett, Thomas Ward, et al.
Journal of Health Economics and Outcomes Research|October 27, 2021
Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in JapanTetsuya Matsumoto, Oliver Darlington, Ryan Miller, et al.
Journal of Comparative Effectiveness Research|June 5, 2018
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaWen Chen, Thomas Ward, Mai Ping Tan, et al.
Pharmacoeconomics - Open|December 6, 2024
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year DataAlison D Griffiths, Robert O Young, Yong Yuan, et al.
Journal of Medical Economics|December 20, 2019
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithmNathan R Hill, Belinda Sandler, Ruth Mokgokong, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics - Open|September 15, 2022
Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling StudyTetsuya Matsumoto, Akira Yuasa, Ryan Miller, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 24, 2007
Cost-utility analysis when not everyone wants the treatment: modeling split-choice biasRichard Lilford, Alan Girling, David Braunholtz, et al.
Cardiovascular Diabetology|January 21, 2009
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational studyPeter Sharplin, Jason Gordon, John R Peters, et al.
Cardiovascular Diabetology|February 18, 2009
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysisPeter Sharplin, Jason Gordon, John R Peters, et al.
Pharmacoeconomics - Open|July 3, 2021
Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision MakingJason Gordon, Angela Stainthorpe, Beverley Jones, et al.
European Journal of Gastroenterology & Hepatology|November 7, 2015
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UKPhil McEwan, Hayley Bennett, Thomas Ward, et al.
Journal of Health Economics and Outcomes Research|October 27, 2021
Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in JapanTetsuya Matsumoto, Oliver Darlington, Ryan Miller, et al.
Journal of Comparative Effectiveness Research|June 5, 2018
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaWen Chen, Thomas Ward, Mai Ping Tan, et al.
Pharmacoeconomics - Open|December 6, 2024
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year DataAlison D Griffiths, Robert O Young, Yong Yuan, et al.
Journal of Medical Economics|December 20, 2019
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithmNathan R Hill, Belinda Sandler, Ruth Mokgokong, et al.
Pageof 7